These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12474570)

  • 1. [Effect of methylprednisolone on emotional functioning of patients with multiple sclerosis].
    Kułakowska A; Drozdowski W; Halicka D; Kochanowicz J; Braszko JJ
    Pol Merkur Lekarski; 2002 Sep; 13(75):200-3. PubMed ID: 12474570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of methylprednisolone on the attention in patients with multiple sclerosis].
    Kułakowska A; Halicka D; Drozdowski W; Braszko JJ
    Pol Merkur Lekarski; 2006 Jan; 20(115):65-8. PubMed ID: 16617739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
    Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Personality features in multiple sclerosis patients with a relapsing-remitting course of the disease].
    Papuć E; Pawłowska B
    Psychiatr Pol; 2005; 39(4):669-78. PubMed ID: 16237972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
    Amato MP; Portaccio E; Goretti B; Zipoli V; Battaglini M; Bartolozzi ML; Stromillo ML; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
    Arch Neurol; 2007 Aug; 64(8):1157-61. PubMed ID: 17698706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuropsychology of mildly disabled patients with relapsing-remitting multiple sclerosis].
    Santiago Rolanía O; Guàrdia Olmos J; Arbizu Urdiain T
    Psicothema; 2006 Feb; 18(1):84-7. PubMed ID: 17296014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
    Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
    J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs].
    Nogales-Gaete J; Aracena R; Díaz V; Zitko P; Eloiza C; Cepeda-Zumaeta S; Agurto P; González C
    Rev Med Chil; 2012 Nov; 140(11):1437-44. PubMed ID: 23677190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiple sclerosis and depression].
    Sánchez López MP; Olivares Pérez T; Nieto Barco A; Hernández Pérez MA; Barroso Ribal J
    Rev Neurol; 2004 Mar 16-31; 38(6):524-9. PubMed ID: 15054715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients.
    Mirowska-Guzel D; Gromadzka G; Kurowska K; Czlonkowski A; Czlonkowska A
    Immunopharmacol Immunotoxicol; 2010 Sep; 32(3):416-21. PubMed ID: 20095806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL; Bueno AM; Devonshire V; Tremlett H;
    Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
    McNicholas N; Patel A; Chataway J
    QJM; 2012 Aug; 105(8):775-80. PubMed ID: 22514268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of neuropsychological testing for guiding treatment decisions in paediatric multiple sclerosis.
    Penner IK; Hubacher M; Rasenack M; Sprenger T; Weber P; Naegelin Y
    Mult Scler; 2013 Mar; 19(3):366-8. PubMed ID: 22740487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coping strategy and anxiety evolution in multiple sclerosis patients initiating interferon-beta treatment.
    Moreau T; Schmidt N; Joyeux O; Bungener C; Souvignet V
    Eur Neurol; 2009; 62(2):79-85. PubMed ID: 19521082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis.
    Goretti B; Portaccio E; Ghezzi A; Lori S; Moiola L; Falautano M; Viterbo R; Patti F; Vecchio R; Pozzilli C; Bianchi V; Cappiello S; Comi G; Trojano M; Amato MP;
    Mult Scler; 2012 Mar; 18(3):329-34. PubMed ID: 21844064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.